



LIST OF TABLES AND FIGURES

LIST OF TABLES

	Page
Table 1.1.1 Sociodemographic characteristics and geographic locations of the patient cohort (N=2,330)	19
Table 1.2.1 Dietary habits, exercise habit and stress level at the time of diagnosis	21
Table 1.2.2 Dietary habits, lack of exercise and high stress level at the time of diagnosis by age group	21
Table 1.2.3 High stress level at the time of diagnosis by occupation and age group	22
Table 1.3.1 Body mass index, bra size and cup size at the time of diagnosis (N=2,330)	23
Table 1.3.2 Family history, personal history of tumours and history of breast diseases at the time of diagnosis	25
Table 1.3.3 Early menarche, late menopause and reproductive history at the time of diagnosis	26
Table 1.3.4 Use of exogenous hormone at the time of diagnosis	27
Table 1.3.5 The ten most common risk factors in the patient cohort	29
Table 1.4.1 Breast screening habits in the two age groups	30
Table 2.1.1 Mode of first breast cancer detection by type of medical care	36
Table 2.1.2 Major presenting symptoms in self-detected patients by type of medical care	37
Table 2.1.3 Number of months from onset of symptoms to first medical consultation by type of medical care	38
Table 2.2.1 Sensitivities and diagnostic results of mammography, breast ultrasound and magnetic resonance imaging (MRI)	40
Table 2.2.2 Sensitivities and diagnostic results of fine needle aspiration (FNA), core needle biopsy (CNB) and excisional biopsy	40
Table 2.2.3 Types of cancer staging methods in 1,880 breast cancer patients	42
Table 2.2.4 Cancer stage at diagnosis by type of medical care	43
Table 2.2.5 Tumour size of invasive breast cancers by type of medical care	44
Table 2.2.6 Number of lymph nodes positives by type of medical care	44
Table 2.2.7 Tumour sizes of in situ breast cancers by type of medical care	45
Table 2.3.1 Histological type, grading, multifocality and multicentricity of 1,853 invasive breast cancers	46
Table 2.3.2 Molecular characteristics of invasive breast cancers	47
Table 2.3.3 Molecular subtypes of estrogen receptor, progesterone receptor and HER 2 receptor in 1,853 invasive breast cancers	47
Table 2.3.4 Histological type, grade, multifocality and multicentricity of in situ breast cancers	48
Table 2.3.5 Molecular characteristics of in situ breast cancers	48
Table 2.4.1 Types of surgical operations in the patient cohort	50
Table 2.4.2 Usage of anthracyclines, taxanes and other drugs by type of medical care	55
Table 2.4.3 Type of radiated regions in the patients with radiation therapy (N=1,381)	56
Table 2.4.4 Percentage of the patients on tamoxifen by cancer stage in each type of medical care	57
Table 2.4.5 Percentage of the patients on aromatase inhibitor by cancer stage in each type of medical care	57
Table 2.5.1 Follow-up of 1,630 subjects	60
Table 2.5.2 Characteristics of breast cancer specific deaths	60
Table 3.2.1 Psychosocial impacts of breast cancer in 1,444 breast cancer patients	67
Table 3.2.2 Psychosocial adjustments and coping strategies for survivorship	70

LIST OF FIGURES

	Page
Figure 1.1.1 Age distribution of the patient cohort (N=2,330)	19
Figure 1.2.1 Distribution of smokers and alcohol drinkers at time of diagnosis by age group	20
Figure 1.3.1 Body mass index at the time of diagnosis by age group	24
Figure 1.3.2 Use of oral contraceptives at the time of diagnosis by age group	27
Figure 1.3.3 Use of hormone replacement therapy at the time of diagnosis by age group	28
Figure 1.3.4 Distribution of patient cohort bearing different number of risk factors at the time of diagnosis	29
Figure 1.4.1 Habits of breast self-examination at the time of diagnosis by education level	31
Figure 1.4.2 Habits of clinical breast examination at the time of diagnosis by education level	31
Figure 1.4.3 Habits of mammography screening at the time of diagnosis by education level	32
Figure 1.4.4 Habits of breast ultrasound screening at the time of diagnosis by education level	32
Figure 2.1.1 Mode of first breast cancer detection in the patient cohort (N=2,130)	36
Figure 2.1.2 Major presenting symptoms in self-detected patients (N=1,645)	37
Figure 2.1.3 Number of months from onset of symptoms to first medical consultation in the patient cohort (N=2,130)	38
Figure 2.2.1 Laterality of 2,130 breast cancers	39
Figure 2.2.2 Locations of breast cancers in breasts (N=2,130)	39
Figure 2.2.3 Mammographic findings of breast cancer patients with diagnostic mammography (N=1,886)	41
Figure 2.2.4 Mammographic density of breasts of the patients with diagnostic mammography (N=1,886)	41
Figure 2.2.5 Cancer stage at diagnosis in breast cancer patients (N=2,130)	42
Figure 2.2.6 Distribution of tumour size of invasive breast cancers	43
Figure 2.2.7 Number of positive lymph nodes in invasive breast cancers	44
Figure 2.2.8 Distribution of tumour size of in situ breast cancers (N=233)	45
Figure 2.3.1 Mammographic findings of in situ breast cancers (N=241)	49
Figure 2.4.1 Type of surgery by age group	51
Figure 2.4.2 Type of surgery by cancer stage	51
Figure 2.4.3 Type of surgery by type of medical care	52
Figure 2.4.4 Type of breast reconstruction employed in the patients aged under 40 and the patients aged 40 or above	52
Figure 2.4.5 Breast reconstruction rate by type of medical care	53
Figure 2.4.6 Type of breast reconstruction by type of medical care	53
Figure 2.4.7 Type of nodal surgery by cancer stage	54
Figure 2.4.8 Chemotherapy rate in the patients with invasive breast cancers at different cancer stages	54
Figure 2.4.9 Type of chemotherapy regimens used in the patients with invasive breast cancers	55
Figure 2.4.10 Type of chemotherapy regimens in the patients with invasive breast cancer by cancer stage	55
Figure 2.4.11 Endocrine therapy rates in the patients with in situ or invasive breast cancers by cancer stage	56
Figure 2.4.12 Forms of endocrine therapy used in the patients with in situ or invasive breast cancers	57
Figure 2.4.13 Targeted therapy rate in the patients with invasive breast cancer by cancer stage	58
Figure 2.4.14 Type of drugs used for targeted therapy in the patients with invasive breast cancer	58
Figure 2.4.15 Type of alternative medicine used in 275 patients	59
Figure 3.1.1 Level of physical discomfort after surgical operation	63
Figure 3.1.2 Level of post surgical physical discomfort by type of surgery	63
Figure 3.1.3 Level of physical discomfort after radiation therapy	64
Figure 3.1.4 Level of physical discomfort after chemotherapy	64
Figure 3.1.5 Level of physical discomfort by chemotherapy regimen	65
Figure 3.1.6 Level of physical discomfort after endocrine therapy	65



Figure 3.1.7	Level of physical discomfort after targeted therapy	66
Figure 3.1.8	Level of physical discomfort after complementary and alternative therapies	66
Figure 3.2.1	Change in outlook by age group	68
Figure 3.2.2	Change in outlook by cancer stage	68
Figure 3.2.3	Change in self-image by age group	69
Figure 3.2.4	Change in self-image by cancer stage	69
Figure 3.2.5	Level of worries about recurrence by age group	71
Figure 3.2.6	Level of worries about recurrence by cancer stage	71